262 related articles for article (PubMed ID: 31157658)
1. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease.
Puri L; Morgan KJ; Anghelescu DL
Curr Opin Support Palliat Care; 2019 Dec; 13(4):402-407. PubMed ID: 31157658
[TBL] [Abstract][Full Text] [Related]
2. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
Nobrega R; Sheehy KA; Lippold C; Rice AL; Finkel JC; Quezado ZMN
Pediatr Res; 2018 Feb; 83(2):445-454. PubMed ID: 28902183
[TBL] [Abstract][Full Text] [Related]
3. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
Neri CM; Pestieau SR; Darbari DS
Paediatr Anaesth; 2013 Aug; 23(8):684-9. PubMed ID: 23565738
[TBL] [Abstract][Full Text] [Related]
4. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature.
Uprety D; Baber A; Foy M
Ann Hematol; 2014 May; 93(5):769-71. PubMed ID: 24232306
[TBL] [Abstract][Full Text] [Related]
5. Lidocaine and Ketamine Infusions as Adjunctive Pain Management Therapy: A Retrospective Analysis of Clinical Outcomes in Hospitalized Patients Admitted for Pain Related to Sickle Cell Disease.
Zavala NA; Knoebel RW; Anitescu M
Front Pain Res (Lausanne); 2022; 3():878985. PubMed ID: 35992021
[TBL] [Abstract][Full Text] [Related]
6. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial.
Lubega FA; DeSilva MS; Munube D; Nkwine R; Tumukunde J; Agaba PK; Nabukenya MT; Bulamba F; Luggya TS
Scand J Pain; 2018 Jan; 18(1):19-27. PubMed ID: 29794277
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Ketamine Infusion for Adjunct Management during Vaso-occlusive Episodes in Adults with Sickle Cell Disease: A Case Series.
Palm N; Floroff C; Hassig TB; Boylan A; Kanter J
J Pain Palliat Care Pharmacother; 2018 Mar; 32(1):20-26. PubMed ID: 29791238
[TBL] [Abstract][Full Text] [Related]
8. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents.
Finkel JC; Pestieau SR; Quezado ZM
J Pain; 2007 Jun; 8(6):515-21. PubMed ID: 17434801
[TBL] [Abstract][Full Text] [Related]
9. Early Initiation of Sub-Anesthetic Ketamine Infusion in Adults with Vaso-Occlusive Crises Is Associated with Greater Reduction in Sickle Cell Pain Intensity: A Single Center's Experience.
Kenney MO; Becerra B; Mallikarjunan A; Shah N; Smith WR
Pain Med; 2022 Dec; 23(12):2042-2049. PubMed ID: 35708641
[TBL] [Abstract][Full Text] [Related]
10. Ketamine Infusion for Pain Control in Acute Pediatric Sickle Cell Painful Crises.
Hagedorn JM; Monico EC
Pediatr Emerg Care; 2019 Jan; 35(1):78-79. PubMed ID: 27902670
[TBL] [Abstract][Full Text] [Related]
11. Oral ketamine for sickle cell crisis pain refractory to opioids.
Jennings CA; Bobb BT; Noreika DM; Coyne PJ
J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):150-4. PubMed ID: 23692261
[TBL] [Abstract][Full Text] [Related]
12. Impact of early analgesia on hospitalization outcomes for sickle cell pain crisis.
Payne J; Aban I; Hilliard LM; Madison J; Bemrich-Stolz C; Howard TH; Brandow A; Waite E; Lebensburger JD
Pediatr Blood Cancer; 2018 Dec; 65(12):e27420. PubMed ID: 30151977
[TBL] [Abstract][Full Text] [Related]
13. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease.
Tawfic QA; Faris AS; Kausalya R
J Pain Symptom Manage; 2014 Feb; 47(2):334-40. PubMed ID: 23856095
[TBL] [Abstract][Full Text] [Related]
14. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.
Sheehy KA; Finkel JC; Darbari DS; Guerrera MF; Quezado ZM
Pain Pract; 2015 Nov; 15(8):E90-7. PubMed ID: 26205912
[TBL] [Abstract][Full Text] [Related]
15. Low-dose ketamine infusions reduce opioid use in pediatric and young adult oncology patients.
Anghelescu DL; Ryan S; Wu D; Morgan KJ; Patni T; Li Y
Pediatr Blood Cancer; 2022 Sep; 69(9):e29693. PubMed ID: 35373875
[TBL] [Abstract][Full Text] [Related]
16. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.
Rollé A; Vidal E; Laguette P; Garnier Y; Delta D; Martino F; Portecop P; Etienne-Julan M; Piednoir P; De Jong A; Romana M; Bernit E
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138299
[No Abstract] [Full Text] [Related]
17. Opioid-sparing effect of intravenous outpatient ketamine infusions appears short-lived in chronic-pain patients with high opioid requirements.
Kapural L; Kapural M; Bensitel T; Sessler DI
Pain Physician; 2010; 13(4):389-94. PubMed ID: 20648208
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement.
Wong CS; Lu CC; Cherng CH; Ho ST
Can J Anaesth; 1997 Jan; 44(1):31-7. PubMed ID: 8988821
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis.
Shah SP; Twilla JD; Kemp L; Phelps GL; Reaves A
J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease.
Alshahrani MS; Asonto LP; El Tahan MM; Al Sulaibikh AH; Al Faraj SZ; Al Mulhim AA; Al Abbad MF; Al Nahhash SA; Aldarweesh MN; Mahmoud AM; Almaghraby N; Al Jumaan MA; Al Junaid TO; Al Hawaj FM; AlKenany S; ElSayed OF; Abdelwahab HM; Moussa MM; Alossaimi BK; Alotaibi SK; AlMutairi TM; AlSulaiman DA; Al Shahrani SD; Alfaraj D; Alhazzani W
Trials; 2019 May; 20(1):286. PubMed ID: 31133061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
